| Segment Information |
The CODM reviews the budget versus actual expense by nature of expense. The following table sets forth our segment loss disclosure for the three and six months ended June 30, 2025 and 2024 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
R&D – Compensation and benefits (1) |
|
$ |
3,217 |
|
|
$ |
3,679 |
|
|
$ |
6,512 |
|
|
$ |
7,165 |
|
R&D – Clinical trial costs |
|
|
2,448 |
|
|
|
2,935 |
|
|
|
5,298 |
|
|
|
5,532 |
|
R&D – Outsourced services & consulting |
|
|
3,132 |
|
|
|
5,363 |
|
|
|
5,514 |
|
|
|
10,042 |
|
R&D – Lab and pharmacology supplies |
|
|
256 |
|
|
|
695 |
|
|
|
546 |
|
|
|
1,399 |
|
R&D – Other costs (2) |
|
|
440 |
|
|
|
465 |
|
|
|
1,036 |
|
|
|
898 |
|
G&A – Compensation and benefits (1) |
|
|
1,528 |
|
|
|
1,645 |
|
|
|
3,102 |
|
|
|
3,192 |
|
G&A – Professional service fees |
|
|
810 |
|
|
|
748 |
|
|
|
1,807 |
|
|
|
1,541 |
|
G&A – Insurance |
|
|
202 |
|
|
|
213 |
|
|
|
420 |
|
|
|
243 |
|
G&A – Other costs (3) |
|
|
618 |
|
|
|
595 |
|
|
|
1,344 |
|
|
|
967 |
|
Facilities related |
|
|
2,400 |
|
|
|
652 |
|
|
|
4,699 |
|
|
|
1,304 |
|
Stock-based compensation and depreciation |
|
|
2,010 |
|
|
|
2,401 |
|
|
|
4,124 |
|
|
|
3,991 |
|
Total operating expense |
|
|
17,061 |
|
|
|
19,391 |
|
|
|
34,402 |
|
|
|
36,274 |
|
Loss from operations |
|
|
(17,061 |
) |
|
|
(19,391 |
) |
|
|
(34,402 |
) |
|
|
(36,274 |
) |
Interest and other income, net |
|
|
1,386 |
|
|
|
2,415 |
|
|
|
2,969 |
|
|
|
3,868 |
|
Segment net loss |
|
$ |
(15,675 |
) |
|
$ |
(16,976 |
) |
|
$ |
(31,433 |
) |
|
$ |
(32,406 |
) |
(1)Excludes stock-based compensation expense. (2)Includes software expense, database subscriptions expense, lab service contract expense, travel expense, and other miscellaneous expenses. (3)Includes travel expense, public & investor relations expense, software expense, employee training & development expense, and other miscellaneous expenses. |